SUBSCRIBE
SUBSCRIBE

Indications

PRESS RELEASES
Press Releases
U.S. FDA grants interchangeability designation to Celltrion’s denosumab biosimilars, STOBOCLO® (denosumab-bmwo) and OSENVELT® (denosumab-bmwo)
October 30, 2025
 · 
13 min read
Press Releases
OPKO Health’s ModeX Therapeutics Enters into Research Collaboration with Regeneron to Develop Multispecific Antibodies for Select Therapeutic Indications
October 30, 2025
 · 
6 min read
Press Releases
VentureMed Group Closes $28M Series C Funding to Accelerate Commercial Adoption and Expand Indications for the FLEX VPTM System
October 30, 2025
 · 
3 min read
Press Releases
IN8bio Presents T cell Engager Data Demonstrating Deep B Cell Depletion for Autoimmune Indications
October 28, 2025
 · 
6 min read
Press Releases
MIRA Pharmaceuticals Initiates Multiple Ascending Dose (MAD) Phase 1 Study of Oral Ketamir-2 and Selects Chemotherapy-Induced Neuropathic Pain as Lead Phase 2a Indication
October 27, 2025
 · 
6 min read
Press Releases
FDA approves expanded pediatric indications for YUFLYMA® (adalimumab-aaty) and unbranded adalimumab-aaty in the United States
October 17, 2025
 · 
18 min read
Press Releases
Bristol Myers Squibb to Present Data at ESMO® 2025 Showcasing Progress of Oncology Portfolio Across Diverse Tumor Types
October 13, 2025
 · 
19 min read
Press Releases
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Re-Files Abbreviated New Drug Application (ANDA) for KETAFREE™, Preservative-Free IV Ketamine
September 30, 2025
 · 
7 min read
Press Releases
Kayothera, Inc. Nominates KAYO-1732, a First-In-Class, Oral Inhibitor of the Retinoid Nuclear Receptor Pathway in Type 2 Diabetes and Cardiometabolic Indications as a Development Candidate
September 23, 2025
 · 
2 min read
Press Releases
Merck Receives Two Positive EU CHMP Opinions for KEYTRUDA® (pembrolizumab), for Subcutaneous (SC) Administration and for New Indication for Earlier-Stage Head and Neck Cancer
September 22, 2025
 · 
19 min read
Press Releases
FDA Approves Merck’s KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph) Injection for Subcutaneous Use in Adults Across Most Solid Tumor Indications for KEYTRUDA® (pembrolizumab)
September 22, 2025
 · 
19 min read
Press Releases
Health Canada approves Celltrion’s Stoboclo® and Osenvelt®(CT-P41), denosumab biosimilars for the treatment of all indications approved for the reference products, Prolia® and Xgeva®, respectively
September 19, 2025
 · 
5 min read
Press Releases
Progress in clinical development for Alzheimer’s and other indications: Galimedix Therapeutics successfully completes Phase 1 study with oral small molecule, GAL-101, an amyloid beta aggregation modulator
September 15, 2025
 · 
4 min read
Press Releases
U.S. FDA Approves Expanded Indication for VONVENDI® [von Willebrand factor (Recombinant)] for Adults and Children with Von Willebrand Disease
September 8, 2025
 · 
12 min read
Press Releases
European Commission Approves Tablet Formulation of BeOne Medicines’ BRUKINSA® for All Approved Indications
August 21, 2025
 · 
4 min read
Press Releases
FDA approves expanded indication for AVTOZMA® (tocilizumab-anoh) intravenous (IV) formulation in cytokine release syndrome (CRS)
August 7, 2025
 · 
8 min read
Press Releases
NanoViricides Discusses the Multi-Billion-Dollar Potential of Its Broad-Spectrum Drug NV-387; Its Effectiveness Against Influenza, Coronaviruses, RSV, MPox and Now Measles Expected to Drive Value
July 24, 2025
 · 
10 min read
Press Releases
Darolutamide receives EU approval in third indication for patients with advanced prostate cancer
July 21, 2025
 · 
6 min read
Press Releases
Acera Surgical Broadens Reach of Restrata® with New FDA Clearance for Soft Tissue Reinforcement
June 26, 2025
 · 
2 min read
Press Releases
FDA Approves Expanded Indications for GE HealthCare’s Vizamyl PET Imaging Agent for Beta Amyloid Detection, Enabling More Precise Care for Alzheimer’s Patients
June 25, 2025
 · 
9 min read
Load More